Gain-of-function mutations in PIEZO1 directly impair hepatic iron metabolism via the inhibition of the BMP/SMADs pathway

Am J Hematol. 2020 Feb;95(2):188-197. doi: 10.1002/ajh.25683. Epub 2019 Dec 9.

Abstract

Dehydrated hereditary stomatocytosis (DHS), or xerocytosis, is an autosomal dominant hemolytic anemia. Most patients with DHS carry mutations in the PIEZO1 gene encoding a mechanosensitive cation channel. We here demonstrate that patients with DHS have low levels of hepcidin and only a slight increase of ERFE, the erythroid negative regulator of hepcidin. We demonstrated that at the physiological level, PIEZO1 activation induced Ca2+ influx and suppression of HAMP expression in primary hepatocytes. In two hepatic cellular models expressing PIEZO1 WT and two PIEZO1 gain-of-function mutants (R2456H and R2488Q), we highlight altered expression of a few genes/proteins involved in iron metabolism. Mutant cells showed increased intracellular Ca2+ compared to WT, which was correlated to increased phosphorylation of ERK1/2, inhibition of the BMP-SMADs pathway, and suppression of HAMP transcription. Moreover, the HuH7 cells, treated with PD0325901, a potent inhibitor of ERK1/2 phosphorylation, reduced the phosphorylation of ERK1/2 with the consequent increased phosphorylation of SMAD1/5/8, confirming the link between the two pathways. Another "proof of concept" for the mechanism that links PIEZO1 to HAMP regulation was obtained by mimicking PIEZO1 activation by cell Ca2+ overload, by the Ca2+ ionophore A23187. There was strong down-regulation of HAMP gene expression after this Ca2+ overload. Finally, the inhibition of PIEZO1 by GsMTx4 leads to phenotype rescue. This is the first demonstration of a direct link between PIEZO1 and iron metabolism, which defines the channel as a new hepatic iron metabolism regulator and as a possible therapeutic target of iron overload in DHS and other iron-loading anemias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anemia, Hemolytic, Congenital* / genetics
  • Anemia, Hemolytic, Congenital* / metabolism
  • Anemia, Hemolytic, Congenital* / pathology
  • Benzamides / pharmacology
  • Bone Morphogenetic Proteins / genetics
  • Bone Morphogenetic Proteins / metabolism*
  • Diphenylamine / analogs & derivatives
  • Diphenylamine / pharmacology
  • Gain of Function Mutation*
  • Gene Expression Regulation
  • Hep G2 Cells
  • Hepcidins / biosynthesis*
  • Hepcidins / genetics
  • Humans
  • Hydrops Fetalis* / genetics
  • Hydrops Fetalis* / metabolism
  • Hydrops Fetalis* / pathology
  • Ion Channels* / genetics
  • Ion Channels* / metabolism
  • Iron / metabolism*
  • Liver / metabolism*
  • Liver / pathology
  • MAP Kinase Signaling System*
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / genetics
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Smad Proteins / genetics
  • Smad Proteins / metabolism*

Substances

  • Benzamides
  • Bone Morphogenetic Proteins
  • HAMP protein, human
  • Hepcidins
  • Ion Channels
  • PIEZO1 protein, human
  • Smad Proteins
  • mirdametinib
  • Diphenylamine
  • Iron
  • MAPK1 protein, human
  • MAPK3 protein, human
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3

Supplementary concepts

  • Xerocytosis, hereditary